Resources Repository
-
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Europe | North America | Health Systems | Infectious Diseases | Preferences/Values | Priority Setting/Ethics | Evidence Synthesis | Value of Information | Cost-Effectiveness Analysis | Technology Assessment | Chronic Disease/Risk | Mental Health | Business/Industry | Economics/Finance | Government/Law | Health/Medicine | Science/Technology -
ReviewPublication 2022Significance of Advanced COVID-19 Diagnostic Testing in Pandemic Control Measures
Over the past two years of the COVID-19 pandemic, the scientific community has mounted significant …
Over the past two years of the COVID-19 pandemic, the scientific community has mounted significant efforts to combat the highly transmissible SARS-CoV-2 virus. Despite substantial progress in vaccines and treatments, leading to lower hospitalization and death rates, the virus has continued to evolve, primarily through mutations. From the onset, diagnostic tests have been crucial in identifying and controlling the virus spread. The scientific world has pioneered various diagnostic techniques, including nucleic acid, antigen, and antibody-based…
North America | Health Systems | Infectious Diseases | Test Performance | Clinical Care | Health/Medicine | Science/Technology -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
Europe | North America | Infectious Diseases | Value of Information | State-Transition | Benefit-Cost Analysis | Policy/Regulation | Economics/Finance -
ArticlePublication 2021Measuring the Impact of COVID-19 Vaccine Misinformation on Vaccination Intent in the U.K. and U.S.
Widespread acceptance of a vaccine for SARS-CoV-2 will be the next major step to fight …
Widespread acceptance of a vaccine for SARS-CoV-2 will be the next major step to fight the COVID-19 pandemic, but high uptake achievement will be a challenge and may be impeded by online misinformation. This article is a randomized controlled trial in the U.K. and the U.S. with the objective to quantify how exposure to online misinformation around COVID-19 vaccines affects intent to vaccinate to protect oneself or others. The authors report that in both countries…
Europe | North America | Infectious Diseases | Decision Psychology | Preferences/Values | Child/Nutrition | Social Determinants | Culture/Society | Health/Medicine | Science/Technology -
ArticlePublication 2020Online Competition between Pro- and Anti-Vaccination Views
Distrust in scientific expertise is dangerous. Opposition to vaccination with a future vaccine against SARS-CoV-2, …
Distrust in scientific expertise is dangerous. Opposition to vaccination with a future vaccine against SARS-CoV-2, the causal agent of COVID-19, for example, could amplify outbreaks as happened for measles in 2019. Homemade remedies and falsehoods are being shared widely on the Internet, as well as dismissals of expert advice. There is a lack of understanding about how this distrust evolves at the system level. Authors provide a map of the contention surrounding vaccines that has…
North America | Health Systems | Infectious Diseases | Decision Psychology | Preferences/Values | Social Determinants | Policy/Regulation | Culture/Society | Government/Law | Health/Medicine | Science/Technology -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
North America | Health Systems | Infectious Diseases | Probability/Bayes | Test Performance | Technology Assessment | Policy/Regulation | Government/Law | Health/Medicine | Global -
ReportPublication 2010Priorities for the National Vaccine Plan
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine …
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine and public health, from research and development of new vaccines to financing and reimbursement of immunization services. The current climate, socially, economically and politically, presents challenges and opportunities to the U.S. to strengthen the existing systems of developing, manufacturing, regulating, distributing, funding, and administering safe and effective vaccines for all people. The authors present recommendations for priority actions intended to…
North America | Health Systems | Infectious Diseases | Evidence Synthesis | Technology Assessment | Chronic Disease/Risk | Policy/Regulation | Economics/Finance | Health/Medicine | Science/Technology -
DataWeb Portal 2024OECD Health Statistics
The Organisation for Economic Co-operation and Development (OECD) Health Database offers a comprehensive source of …
The Organisation for Economic Co-operation and Development (OECD) Health Database offers a comprehensive source of comparable statistics on health and health systems across OECD countries. These data serve to facilitate and support comparative analyses, and can be useful for researchers, educators and policy makers looking to draw lessons from international comparisons of diverse health systems. General categories of data include population demographics, health status and determinants of health, as well as data on the societal responses to health…
Europe | North America | Health Systems | Health Outcomes | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Social Determinants | Policy/Regulation | Economics/Finance | Education/Labor | Health/Medicine | Science/Technology | Latin America & Caribbean | Oceania -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
North America | Health Systems | Infectious Diseases | Test Performance | State-Transition | Microsimulation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Economics/Finance | Health/Medicine | Global